Hansa Medical AB (STO: HMED) on Tuesday reported net loss of SEK37,527,000, or SEK1.07 per diluted share, for the third quarter of 2017.

This was a decline over net loss of SEK26,926,000, or SEK0.83 per diluted share, in Q3 2016.

Net revenues for the quarter were SEK678,000, as compared with SEK907,000 in Q3 2016.

Hansa Medical is a biopharmaceutical company developing novel immunomodulatory enzymes for transplantation and acute autoimmune diseases. The lead project IdeS is a proprietary antibody-degrading enzyme currently in late-stage clinical development for kidney transplant patients.

(EUR1.00=SEK9.91)